Avelumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown efficacy in renal cell carcinoma (RCC) but is associated with immune-related adverse events (irAEs), including rare neurological complications such as myasthenia gravis (MG). This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.